Semax Dosing & Reconstitution Guide

Semax can be administered via two primary routes: intranasal and subcutaneous. Research suggests that the intranasal route is preferred due to its favorable pharmacokinetics and direct access to the central nervous system. Studies indicate a dosing frequency of 2 to 3 times daily for intranasal administration, while subcutaneous administration is typically conducted once daily. The effective dose range reported for intranasal use is 200 to 600 mcg per nostril, taken 2 to 3 times daily, whereas for subcutaneous use, a daily dose of 200 to 600 mcg is indicated. Cycles of 2 to 4 weeks of administration followed by 1 to 2 weeks off are suggested in the literature to optimize outcomes. Timing of doses may also be considered, with morning administration linked to enhanced cognitive performance and the option to include an afternoon dose for sustained effects.

For research applications, Semax is typically provided in a lyophilized form, with a standard vial size of 5 mg. To achieve a usable solution, the recommended volume of sterile water for reconstitution is 5 mL, resulting in a final concentration of 1 mg/mL. This concentration facilitates precise dosing for experimental protocols. It is crucial to handle the reconstitution process with care to maintain the integrity of the peptide and ensure accurate dosing in subsequent applications. Researchers should be aware of the potential for variability in reconstitution practices and the importance of maintaining consistent methods across studies.

The titration schedule for Semax has been explored in various studies, with initial dosing typically set at 200 mcg administered intranasally twice daily during the first two weeks. Subsequent adjustments may increase the dose to a range of 400 to 600 mcg, taken 2 to 3 times daily, starting from the third week onward. This gradual titration allows researchers to assess individual responses and optimize dosing based on observed effects. It is essential to recognize that the response to Semax can vary significantly among subjects, necessitating careful monitoring and consideration of individual variability in research contexts.

Proper storage conditions are vital for maintaining the stability and efficacy of Semax. In its lyophilized state, Semax should be stored at temperatures of −20 °C (−4 °F) to preserve its integrity until reconstitution. Once reconstituted, the peptide must be kept refrigerated at temperatures between 2 to 8 °C (35.6 to 46.4 °F) and is generally recommended for use within 28 days. Researchers should ensure that storage protocols are strictly followed to prevent degradation and maintain the peptide's functional properties throughout the study period.

Semax is noted for its generally favorable safety profile, with studies reporting uncommon mild side effects and no potential for dependence. Its origin as an ACTH fragment suggests it has a brain-selective mechanism that minimizes systemic side effects. However, due to its intranasal administration, mild nasal irritation may occur, highlighting the importance of proper spray technique during use. Caution is advised for specific populations; for instance, the safety of Semax during pregnancy and breastfeeding has not been established. Additionally, acute psychosis presents a theoretical concern due to possible dopaminergic enhancement, and individuals with mood disorders should approach Semax with caution due to potential interactions with dopamine pathways.